Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Fentanyl Spray for Breakthrough Cancer Pain
NCT01429051Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2011
- Primary completion
- Jan 2013
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of fentanyl in breakthrough pain, sponsored by Takeda. Primary endpoint: Pain Intensity Difference at 10 Minutes. Started Aug 2011; status: completed.
02
Drugs
fentanyl
03
Conditions
breakthrough pain
Beyond the preview
Go deeper on NCT01429051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01429051.